论文部分内容阅读
Purpose：To evaluate the safety and therapeutic effects of selective intraarterial rAd-p53 infusion combined with chemotherapy for advanced oral carcinoma．Methods：36patients with advanced SCC or ACC in oral region were subdivided into two groups．Allpatients underwent unilateral or bilateral retrograde selective catheterization of ECA．Through the arterial pumps，rAd-p53 combined with chemothereutic agents was administrated to group Ⅰ(7 patients)，rAd-p53 was administrated to group Ⅱ(6 patients)，andchemomereutic agents were administrated to group Ⅲ(10 patients)．Results：The complete response(CR)rate of group Ⅰ(28.57％) Was higher than that of groupⅡ (16.67％)and groupⅢ(10％).No replication-deficient virus Was detected in patients serum，urine or sputum at any assay. Comparing with group Ⅲ，the clinical toxic syndromes and complications in the combination therapy group were significantly decreased vs．that of chemotherany group for both the number of cases and the extent(P<0.05)The transactivation of Bax and inactivation of Bcl-2 were only observed in group Ⅰ and Ⅱ．Conclusion：Routine chemotherapy combined with rAd-p53 infusion can increase the curative effect and decrease the toxic implication of cnemomerapy．